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Abstract
A combined composition of the extracted powders from Hippocampus kuda and Rhizoma Homalomenae together
with honey in a form of medical pill (named as BRONAS) for the treatment of asthma has thoroughly been
investigated under this study. BRONAS has shown its high anti-inflammatory effects and strong inhibition upon the
pathogenesis of asthma. In comparison with other treatments without using BRONAS, the restoration of patients’
health was improved by a factor of 2–3.
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Introduction
Asthma is a chronic disease characterized by inflammation
of the airways (Buse and Lemanske 2001), a complex dis-
order characterized by variable and recurring symptoms,
airflow obstruction, bronchial hyperresponsiveness, and
an underlying inflammation. The interaction of these fea-
tures determines the clinical manifestations and severity
of asthma, and it has been reported as a disease of increas-
ing prevalence (Expert Panel Report 3: Guidelines for the
diagnosis and management of asthma. NIH Publication
No. 07–4051. 2007).
The pathogenesis of asthma is unknown but imbalances
between oxidants and antioxidants are believed to play a
fundamental role. One key component of the oxidant-
antioxidant hypothesis centers on the huge burden of oxi-
dants derived from inflammatory cell infiltration into the
lung. The eosinophil, in particular, is implicated as a major
source of oxidative injury, including protein nitration (Mac-
Pherson et al. 2011). Dysfunctional mitochondria in lung
cells are another potential source of oxidants. Mitochon-
drial injury to airway epithelium occurs in murine models
of allergic asthma (Aguilera-Aguirre et al. 2009; Mabalirajan
et al. 2008). There is evidence to support its role in human
asthma as well, including increased oxidative injury to
mitochondrial epithelial cell superoxide dismutase (SOD)
(Comhair et al. 2005), enhanced mitochondrial proliferation
in bronchial smooth muscle (Trian et al. 2007), and muta-
tions in mitochondrial DNA (Reddy 2011). Overall, this
oxidative burden, generated by both inflammatory and lung
cells, can overwhelm antioxidant defense to cause oxidant
stress during asthma. Thisk stress can alter or inactivate the
function of essential proteins, lipids and nucleic acids cul-
minating in severe cell injury, dysfunction and death.
Among many unknown and complicated mechanisms,
involvement of airways inflammation with an oxidant/anti-
oxidant imbalance such as reactive oxygen species (ROS)
can lead to lung injury as a result of direct oxidative dam-
age to epithelial cells and cells shedding. As inflammation
is often associated with an increased generation of reactive
oxygen species (ROS), it is rational to surmise that an oxi-
dant stress could be mechanistically important in asthma.
ROS have been shown to be associated with the pathogen-
esis of asthma by inducing bronchial hyperreactivity as well
as directly stimulating histamine release from mast cells and
mucus secretion from airway epithelial cells (Ryszard 2000).
The great external surface area (1–2) m2 of the human
airway epithelium plus its direct contact with the environ-
ment, makes the respiratory tract a major target for oxida-
tive injury from inhaled oxidants such as cigarette smoke,
ozone, hyperoxia, nitrogen and sulphur oxides and other
airborne pollutants. It has been well recognized that bio-
logical systems are capable of forming highly reactive
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moieties, both free radicals and non-radicals named re-
active oxygen species (ROS) and reactive nitrogen spe-
cies (RNS). Free radicals can especially be generated in
a wide variety of chemical and biological systems, in-
cluding the formation of plastics, the ageing of paints,
the combustion of fuels and in the human body. In
living organisms, the levels of free radicals and other
‘reactive species’ are controlled by a complex web of
antioxidant defences, which minimize (but do not com-
pletely prevent) oxidative damage to biomolecules
(Roberfroid and Calderon 1995; Gaston et al. 1994;
Halliwell (2005).
These biologically active species serve in cell signaling as
messenger molecules of the autocrine or paracrine system
(Saran and Bors 1989; Suzuki et al. 1997 ) and also in host
defense, (biocidal effects against microbial and tumor
cells) (Babior 1978) but their excessive production may re-
sult in tissue injury and inflammation (Halliwell et al.
1992; Gutteridge and Halliwell 1994). Reportedly, any ex-
cessive production of oxidants is kept to a minimum by a
well coordinated and efficient endogenous antioxidant
defense mechanism. It has been proposed that a deficit in
the precise balance between exposure to oxidants and en-
dogenous antioxidants results in oxidative stress which ap-
pears to be involved in the pathogenesis of a growing
number of diseases, including lung pathologies such as re-
spiratory distress syndrome, asthma, idiopathic and iatro-
genic pulmonary fibrosis, cystic fibrosis, HIV-associated
lung disease, lung cancer and other pulmonary diseases
and conditions (Clement and Housset 1996; Barnes 1995) .
As excessive ROS levels damage lipids, proteins and nu-
cleic acids through oxidation and thus are associated with
various diseases, such as atherosclerosis, arthritis, neurode-
generative disorders, and cancers , a regular supplement of
antioxidants can assist the endogenous defense systems to
counterbalance the harmful effects of excessive ROS
(Balsano and Alisi 2009; Kaur and Geetha 2006).
There has recently been a remarkable increment in sci-
entific articles dealing with oxidative stress (Urguiaga and
Leighton 2000). Consequently, knowledge about reactive
oxygen and nitrogen species metabolism; definition of
markers for oxidative damage; evidence linking chronic
diseases and oxidative stress; identification of flavonoids
and other dietary polyphenol antioxidants present in plant
foods as bioactive molecules; and data supporting the
idea that health benefits associated with fruits, vegetables
in the diet are probably linked to the polyphenol antioxi-
dants they contain. In addition, more than 8,000 poly-
phenolic compounds have been identified in various plant
species and reported to possess many useful properties in-
cluding antiallergic, antiinflammatory, antimicrobial, anti-
viral, antioxidant, oestrogenic, enzyme inhibition, vascular
and cytotoxic anti- tumor activity (Pandey and Rizvi 2009;
Asha et al. 2012).
According to Ji-Xiao Zhu et al., among many other
contained phenolic compounds plants, Rhizoma Homa-
lomenae has been shown to be positive linear correlations
between total phenolic content and antioxidant activity of
the extracts in the DPPH (R = 0.9817), ABTS (R = 0.9873),
b-carotene/linoleic acid (R = 0.8347) and reducing power
(R = 0.9876) tests, respectively.
Another source of natural antioxidants is naturally oc-
curring from traditional Chinese medicines sources, have
been identified as free radical or active oxygen scavengers
(Duh 1998; Pan et al. 2007). Natural antioxidants can pro-
tect the human body from free radicals and retard the pro-
gress of many chronic diseases as well as retard lipid
oxidative rancidity in foods or medicinal materials (Kang
et al. 2008). Among the many mentioned sources of natur-
ally occurring antioxidant, Seahorse (Hippocampus kuda
Bleeker) has been well known for its special medicinal
composition. According to Zhong-Ji Qian et al., the metha-
nol extracts of seahorse contained high amount of phenolic
compounds and those extracts exhibited good antioxidant
activity by effectively scavenging various free radicals such
as DPPH radicals, hydroxyl radicals, superoxide anion radi-
cals, alkyl radicals, and reducing the ferric to ferrous ion in
different antioxidant systems.
In a search for treatment that might stop the recurrent
attacks of breathlessness and wheezing to make it more
susceptible to at least, providing relief for asthmatic pa-
tients, and if possible to treat the asthmatic disease, a
method has emerged that seems to be extremely useful for
application of natural sources of antioxidants for treat-
ment of asthma. The method was using finely extracted
powders from the seahorse (Hippocampus kuda) and
Rhizoma Homalomenae (with a ratio of 1: 1 w/w) in honey
to form into pill of 500mg. All the hand-rolled pills were
dried in an oven at 55°C until the moisture content of the
pill was consistent.
In this paper, successful application of extracted pow-
ders from the seahorse (Hippocampus kuda) and Rhizoma
Homalomenae together with honey in the form of medical
pill for treatment of asthma is reported.
Materials and methods
Preparation of extracts from seahorse (Hippocampus kuda)
The antioxidant extracts were prepared by adopting the
method of Zhong-Ji Qian to check the total phenolic con-
tent and determine the total antioxidant activity.
Preparation of extracts from Rhizoma Homalomenae
The plant materials of Rhizoma Homalomenae used in this
study was donated by DUC- HUNG- a traditional medi-
cine shop in Nhatrang City- a central part of Vietnam. The
dried materials were ground to the fine powder and passed










































The sieved powder was subjected to water distillation for
5 hrs by adopting the method of Zeng et al. 2011.
Preparation of medicinal pills
In this study, a dosage of 500mg pill was prepared and
named as BRONAS, and described as below:
BRONAS was prepared from 200 mg of dried extract
powder of Hippocampus kuda*, 200 mg of dried extract
powder of Rhizoma Homalomenae** and 130 mg of
honey***, and then hand – rolled into pills of around
500 mg, each.
Notes
*The moisture content of the dried extract powder of
Hippocampus kuda was 3%.
**The moisture content of the dried extract powder of
Rhizoma Homalomenaee was 3%.
***The moisture content of the used honey was 17%.
All the hand- rolled pills were dried in an oven at 55°C
for 34 to 46 hours. Moisture content of the pill was de-
termined by the standard AOAC method (AOAC 2000)
Determination of total antioxidant activity of BRONAS
The antioxidant activity of BRONAS was determined right
after drying the pills to the consistent moisture content.
The antioxidant potential of BRONAS was determined on
scavenging activity of the DPPH Free- Radical by adopting
the method described by Sadhu et al. (2003).
The maximum absorption (λ max) of a stable DPPH
in methanol is 520 nm and the results are expressed as
IC50 values. The percent inhibition, radical scavenging
capacity was calculated using the following equation:
DPPH scavenged %ð Þ ¼ A control−A sampleð Þ
A control x 100
Where: A control = Absorbance of DPPH alone.
A sample = Absorbance of DPPH along with different
concentrations of extracted sample.
IC50 was calculated from the slope obtained by plot-
ting a graph of concentration versus % inhibition.
According to Molyneux P (Molyneux 2004) DPPH is the
molecule of 1,1-diphenyl-2-picrylhydrazyl (α, α-diphenyl β
picrylhydrazyl) characterized as a stable free radical by
virtue of the delocalization of the spare electron over the
molecule as a whole, so that the molecules do not dimerize,
as would be the case with most other free radicals. The
delocalization also gives rise to the deep violet colour, char-
acterized by an absorption band in ethanol solution cen-
tered at about 520 nm. When a solution of DPPH is mixed
with that of a substance that can donate a hydrogen atom,
then this gives rise to the reduced form. With the loss of
this violet colour (although there would be expected to be a
residual pale yellow colour from the picryl group still
present). Representing the DPPH radical by Z* and the
donor molecule by AH, the primary reaction is Z* + AH =
ZH + A*
Where:
– ZH is the reduced form
– A* is free radical produced in this first step.
The latter radical will then undergo further reactions
which control the overall stoichiometry, that is, the
Figure 1 The DPPH free radical scavenging of the BRONAS sample.
Table 1 OD values after being measured in triplicate
Blank 200 mg/L 400 mg/L 600 mg/L 800 mg/L 1000 mg/L
0.53 0.40 0.38 0.28 0.24 0.19
0.51 0.41 0.33 0.25 0.22 0.10
0.53 0.42 0.37 0.30 0.23 0.21
Mean 0.52 0.41 0.36 0.28 0.23 0.20
SD 0.01 0.01 0.02 0.03 0.01 0. 01
CV (%) 2.10 1.72 6.30 9.54 5.51 4.30










































number of molecules of DPPH reduced (decolorized) by
one molecule of the reductant.
In this study, stock solutions of the BRONAS sample
were used for preparing various concentrations of 200,
400, 600, 800 and 1000 (mg/L).
Patients
This study was performed at the Home Clinic, 345 D5
Street, Binh Thanh District of Ho Chi Minh city,
Vietnam between September 2011 to early April 2013.
Ninety two asthmatic patients (55% males and 45% fe-
males) who come from different parts of Vietnam, were
randomly selected and included in the study. Their age
range was 12–65 years. All Patients were desperately
suffering from disease of asthma and all of them were
many times hospitalized and measured value of FEV1/
FVC were from 50% to 60%, of which the shortest dis-
ease history was 3 years and the longest was 11 years. It
is worth noting here that most of the participating pa-
tients experienced a set of clinical symptoms which re-
sult in the sensation of difficulty breathing such as
Spasm of the bronchial muscles and shortness of breath-
ing, cough, expectoration, and prolonged expiratory
phase with wheezing. In addition, all of the participating
patients were those, who had ever used high doses of in-
haled corticosteroids and particularly long acting inhaled
β2-adrenergic agonists as the relief of bronchial constric-
tion to reduce the asthmatic episodes.
Pulmonary functions test was performed by Spirometry
test, adopting the method of Faruk et al. 2010 for checking
possible effects of the given medicines on the treated pa-
tients. By applying this, a total computerized spirometer
(Discom-14 Autospiror, Chest Corporation Tokyo, Japan)
that measures Forced Volume Capacity (FVC), Forced
Expiratory Volume in First Second (FEV1), Peek Expira-
tory Flow Rate (PEFR), and Maximal Mid-expiratory Flow
Rate (MMEFR) was extensively applied as it would provide
predicted values.
The patients were then randomly allocated to 2 groups
of A and B. The group A of 40 (18 Males: 22 Females)
patients was given PREDISONE with a single dose of
10 mg/kg of body weight, daily for each 21 days and
stopped for pulmonary function check. The group B (24
Male: 28 Female) was given BRONAS with a single dose
of 1200 mg/kg of body weight, daily for 21 days and
stopped for pulmonary function check as well. The
group A was then given the same dose of BRONAS as
to the group B for 21 days for further comparing the
anti-inflammatory effect of BRONAS with the anti-
inflammatory effect of PREDISONE.
Data analysis
All data are expressed as means ± standard deviation
representative of similar tests carried out in triplicate. Stat-
istical differences were determined by student’s t-test in
which, p<0.05 was considered as statistically significant.
Ethics
All participated patients gave their consent prior to par-
ticipation in the study.
Table 2 The effects of BRONAS and PREDISONE on pulmonary functions test
Drug FVC % FEV1 % MMEFR % PEFR
Before After Before After Before After Before After
PREDISONE 63.45 ± 11.94 65.55 ± 12. 50 51.14 ± 11.63 *54.78 ± 12.20 50.28 ± 22.45 51.72 ± 11.60 2.96 ± 1.34 3.57 ± 2.32
BRONAS 61.38 ± 15.60 *69.35 ± 5. 32 55.39 ± 15.63 *65.32 ± 5.16 53.28 ± 22.45 *62.05 ± 3.60 3.26 ± 1.54 *5.94 ± 2.50
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Data on total antioxidant activity of BRONAS were
shown in the Table 1 and Figure 1. The values obtained
were also shown that the DPPH scavenging effect in per-
centage of BRONAS were three times higher than those
extracted from green tea using the same method of ex-
traction (Yen and Chen 1995)
The Forced Volume Capacity (FVC), Forced Expiratory
Volume in First Second (FEV1), Peek Expiratory Flow
Rate (PEFR), and Maximal Mid-expiratory Flow Rate
(MMEFR) were extensively applied for determining the
response to the therapy and monitoring the rate of pro-
gression. The results have been summarized and shown in
the Table 2 and Figure 2.
The ratio of FEV1 to FVC (v/v) after treatment was
calculated using the formula:
FEV 1after treatment
FVCafter treatment
¼ Value in percentage
The ratio of FEV1 to FVC (v/v) after 21 days of treat-
ment with PREDNISONE was 84.50%.
The ratio of FEV1 to FVC (v/v) after treatment with
BRONAS was 94%.
As the ratio of FEV1 to FVC (v/v) after 21 days of
treatment with PREDNISONE was improved but lower
(84.50%) than the one obtained from the treatment with
BRONAS (94%) in the same period of treatment process,
the asthmatic patients in Group A was then continu-
ously given BRONAS with a single dose of 1200 mg/kg
daily for another 21 days of treatment. The collected
data in this stage of treatment has been summarized and
shown in the Table 3 and Figure 3.
After all the all ninety two patients having had treat-
ment with BRONAS as given dose in the treating
process mentioned above, sets of pulmonary functions
test were conducted and found that till the 83th day of
treatment, all the asthmatic patients were fully or almost
fully recovered. The result of pulmonary functions test
has been summarized and shown in Figure 4.
This statement has been consolidated by the fact that
no clinical symptoms of the severe asthmatic disease
such as Spasm of the bronchial muscles and shortness of
breathing, cough, expectoration, and prolonged expira-
tory phase with wheezing were seen again.
Discussion
From the Table 2, it could be reasoned that there was no
significant increase in FVC%, MMEFR% and PEFR but
only FEV1% by using single PREDNISONE in group A.
In addition, the ratio of FEV1 to FVC (v/v) after 21 days
of treatment was 84.50%.
In group B, a significant improvement in Pulmonary
Function Tests associated with improvement in patients’
clinical conditions was observed. After taking the BRONAS
for the same period of treatment, the ratio of FEV1 to FVC
(v/v) was pretty high (94%).
Data collected from the oral administration of BRONAS
of patients in group A, of which shown in Table 3 and
Figure 4 would again support and explain the beneficial ef-
fect of taking BRONAS in reducing the incidence of
asthma when the ratio of FEV1 to FVC (v/v) was around
97.50%.
FEV1 has been found to be a better physiologic index
than PEFR in the measurement of airflow obstruction
(Christophe et al. 1998). So in this study, the values of PEFR
were used as a reference to possibly support and/or explain
Table 3 The effects of BRONAS on pulmonary functions test in the post treatment of PREDISONE
Drug FVC % FEV1 % MMEFR % PEFR
Before After Before After Before After Before After
BRONAS 65.63 ± 12.44 *73.80 ± 9.67 62.34 ± 14.21 *71.95 ± 10.18 52.34 ± 19.16 *60. 92 ± 11.06 3.15 ± 1.75 *5.86 ± 2.40
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the beneficial effect of orally administering the prescribed
and prepared medical tablet/ pill in reducing, even treating
the incidence of asthma.
The strong antioxidant properties of the BRONAS may
be attributed to the presence of the combined bioactive
antioxidant compounds from the extract of Hippocampus
kuda and those of Rhizoma Homalomenae. Based on the
report of Zhong et al. (2008), the extracted antioxidants
from Hippocampus kuda contained effective reducing
power, DPPH radical scavenging, hydroxyl radical scaven-
ging, superoxide radical scavenging, alkyl radical scaven-
ging and inhibitory intracellular ROS. Zheng and Wang
(2001) reported that the strong antioxidant properties of
the Rhizoma Homalomenae extracts may be due to the
presence of phenolics compounds such as protocatechuic
acid, vanillic acid, syringic acid, caffeic acid, p-coumaric
acid, ferulic acid and apigenin. Phenolic acids are the
main phenols consumed by humans (Ghasemzadeh and
Ghasemzadeh 2011). The six phenolics mentioned above
are all prominent and naturally occurring, and all of
them individually possess potent antioxidant activity
(3 Joskova et al. 2013; Gao et al. 2012). The honey was
intentionally used with the dried extract powder of
Rhizoma Homalomenae and that of Hippocampus kuda
since it has been scientifically considered as an anti-
microbial agent and chelating in traditional medicine.
In addition, there is a great variety of minor compo-
nents, including phenolic acids and flavonoids (Natella
et al. 1999; Joskova et al. 2013), the enzyme glucose oxi-
dase, ascorbic acid, carotenoids, organic acids, amino
acids, proteins and α-tocopherol (Kesic et al. 2009).
By and large, the results obtained from this study
showed that BRONAS can protect cellular components
from many types of oxidative stress by both free radical
scavenging mechanism and stabilizing the cell membranes
and this may explain the improvement that occurred in
both dynamic performance of the lung in moving air and
the elastic recoil force of the lung, especially when the
ratio of FEV1 to FVC reached at least 94%.
Conclusion
The study demonstrates that the combined antioxidants
from extracted powders of Hippocampus kuda and
Rhizoma Homalomenae together with honey in a form of
medical pill (BRONAS) can help improve the treatment of
asthma. BRONAS can be used to replace synthetic antiox-
idants, which are being restricted due to their side effects
such as carcinogenicity. In addition, BRONAS can be pre-
pared at a lower cost and in a more friendly way.
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